Kura Oncology Leukemia Drug Approval – First FDA Clearance
- On December 7, 2023, the Food and Drug Administration approved Komzifti (quizartinib), a new treatment for relapsed or refractory acute myeloid leukemia (AML) with a specific genetic mutation.
- Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow characterized by the rapid growth of abnormal white blood cells.
- A mutation in the nucleophosmin 1 (NPM1) gene is one of the most common genetic abnormalities in AML, occurring in roughly 30% of cases (National Cancer Institute, AML...
“`html
Komzifti Approved: FDA Greenlights Novel Leukemia Treatment
Table of Contents
On December 7, 2023, the Food and Drug Administration approved Komzifti (quizartinib), a new treatment for relapsed or refractory acute myeloid leukemia (AML) with a specific genetic mutation.
Understanding Acute Myeloid Leukemia and NPM1 Mutations
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow characterized by the rapid growth of abnormal white blood cells. according to the American Cancer Society,approximately 20,940 adults will be diagnosed with AML in the United States in 2023 (American Cancer Society, Key Statistics). The prognosis for AML varies substantially depending on several factors, including genetic mutations.
A mutation in the nucleophosmin 1 (NPM1) gene is one of the most common genetic abnormalities in AML, occurring in roughly 30% of cases (National Cancer Institute, AML Genetics). This mutation frequently enough leads to a more aggressive form of the disease and can make treatment more challenging.
Komzifti: How it Works and Clinical Trial Data
Komzifti (quizartinib) is a tyrosine kinase inhibitor (TKI) specifically designed to target and block the activity of FLT3, a protein often overactive in AML cells with the NPM1 mutation. The drug works by interfering with the signaling pathways that promote cancer cell growth and survival.
The FDA approval is based on data from the Phase 3 QuALiTy trial, a randomized, controlled study evaluating Komzifti in patients with relapsed or refractory AML harboring the NPM1 mutation. The study demonstrated that Komzifti significantly improved overall survival compared to standard chemotherapy (Kura Oncology, QuALiTy Trial Topline Results). Specifically, the median overall survival was 7.2 months with Komzifti versus 4.7 months with standard chemotherapy (hazard ratio = 0.67; p = 0.0006).
| Outcome | Komzifti (Quizartinib) | Standard Chemotherapy |
|---|---|---|
| Median Overall survival (months) | 7.2 | 4.7 |
| Hazard Ratio | 0.67 | – |
| p-value | 0.0006 | – |
Common side effects observed in the QuALiTy trial included nausea, vomiting, diarrhea, fatigue, and febrile neutropenia (low white blood cell count with fever) (FDA, Komzifti Approval Summary).
FDA Approval and Future Outlook
The FDA granted Komzifti Priority Review and Breakthrough Therapy designation, expediting its development and review process. the approval marks a important advancement in the treatment of AML patients with the NPM1 mutation, offering a targeted therapy option where limited alternatives previously existed. The FDA’s approval letter is available on the agency’s website (FDA, Komzifti Approval Summary).
Kura Oncology, the manufacturer of Komzift